Sugi Predict

Sugi Predict / Compounds / SCHEMBL435762

SCHEMBL435762

SCHEMBL435762

C1CCC(C2CCC2)CC1

nearest known ligand 0.80

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.80
▸ HSD17B10 Q99714 1/20 0.38
▸ SLC18A3 Q16572 1/20 0.38
▸ ADH1A P07327 2/20 0.33
▸ THRB P10828 1/20 0.33
▸ CES2 O00748 1/20 0.33
▸ CES1 P23141 1/20 0.33
▸ HSD11B1 P28845 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ NOS1 P29475 1/20 0.32
▸ NOS2 P35228 1/20 0.32
▸ ADH1C P00326 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10783863 1.00 ALDH1A1 (0.80) ALDH1A1HSD17B10SLC18A3ADH1ATHRB
SCHEMBL17556613 1.00 ALDH1A1 (0.80) ALDH1A1HSD17B10SLC18A3ADH1ATHRB
SCHEMBL3762881 1.00 ALDH1A1 (0.80) ALDH1A1HSD17B10SLC18A3ADH1ATHRB
SCHEMBL31443055 1.00 ALDH1A1 (0.80) ALDH1A1HSD17B10SLC18A3ADH1ATHRB
SCHEMBL10596318 1.00 ALDH1A1 (0.80) ALDH1A1HSD17B10SLC18A3ADH1ATHRB
SCHEMBL335119 1.00 ALDH1A1 (0.80) ALDH1A1HSD17B10SLC18A3ADH1ATHRB
SCHEMBL8493093 1.00 ALDH1A1 (0.80) ALDH1A1HSD17B10SLC18A3ADH1ATHRB
SCHEMBL5160979 1.00 ALDH1A1 (0.80) ALDH1A1HSD17B10SLC18A3ADH1ATHRB
Biphenyl SCHEMBL2997707 0.95 ALDH1A1 (0.89) ALDH1A1HSD17B10SLC18A3THRBCES2
SCHEMBL7741464 0.95 ALDH1A1 (0.89) ALDH1A1HSD17B10SLC18A3THRBCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023143370-A1 NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND AS WELL AS COMPOSITION AND PHARMACEUTICAL USE THEREOF 四川海思科制药有限公司 2023-08-03 — — WO claimed
WO-2023143384-A1 COMPOUND FOR INHIBITING OR DEGRADING HPK1 KINASE AND MEDICAL USE THEREOF 四川海思科制药有限公司 2023-08-03 — — WO claimed
WO-2023016518-A1 HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF 四川海思科制药有限公司 2023-02-16 — — WO claimed
US-20210155610-A1 Iridinesulfonamide Compound And Use Method Thereof LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) 2021-05-27 — — US claimed
EP-2318363-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS Nuevolution A/S (DK) 2011-05-11 — — EP claimed
WO-2009152824-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2009-12-23 — — WO claimed
EP-2059519-A2 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2009-05-20 — — EP claimed
WO-2008060476-A2 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-05-22 — — WO claimed
US-6187916-B1 Process for the preparation of taxane derivatives and β-lactam intermediates therefor RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 2001-02-13 — — US claimed
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-11 — — US disclosed
CN-117736362-A Polymer, chemically amplified positive resist composition, resist pattern forming method, and blank mask 信越化学工业株式会社 2024-03-22 — — CN disclosed
WO-2024033845-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-02-15 — — WO disclosed
CN-112236423-B Piperidinyl-3- (aryloxy) propanamides and propionic acid esters 武田药品工业株式会社 2024-02-06 — — CN disclosed
WO-2023194964-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-12 — — WO disclosed
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds GILEAD SCIENCES, INC. 2007-01-11 — — US disclosed
US-20060115815-A1 Method and compositions for identifying anti-hiv therapeutic compounds GILEAD SCIENCES, INC. 2006-06-01 — — US disclosed
US-20040067436-A1 Polymerizable silicon-containing compound, manufacturing method, polymer, resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2004-04-08 — — US disclosed
EP-0916673-B1 6-Amino purine derivatives having PDE-IV inhibition activity EURO CELTIQUE SA (LU) 2003-01-29 — — EP disclosed
US-4424392-A HYDROFORMYLATION OF UNSATURATED SILANE, COUPLERS UNION CARBIDE CORPORATION (US) 1984-01-03 — — US disclosed
EP-0089690-A1 Aldehyde containing hydrolyzable silanes UNION CARBIDE CORPORATION (US) 1983-09-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12005054-B2 Piperidinyl-3-(aryloxy)propanamides and propanoates SSTR4, SSTR3, NPY4R ALDH1A1 1476/4885HSD17B10 3693/4885SLC18A3 2082/4885
US-20210155610-A1 Iridinesulfonamide Compound And Use Method Thereof IDH1, IDH3B, IDH3A ALDH1A1 72/4885HSD17B10 208/4885SLC18A3 4259/4885
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds PPA1, PNP, PPME1 ALDH1A1 3337/4885HSD17B10 1703/4885SLC18A3 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.